Virus therapy takes on Hard-to-Treat cancers
NCT ID NCT07584668
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new drug called EM-I-2024, made from a modified enterovirus, in 24 adults with advanced solid tumors that cannot be surgically removed and have not responded to other treatments. The drug is given either intravenously or directly into the artery feeding the tumor, depending on the patient's condition. The main goal is to check safety and find the best dose, while also looking at how the virus behaves in the body and any signs of tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EM-I-2024 (a modified enterovirus)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong
This is a very early, small Phase 1 trial with only 24 participants. The main goal is safety, not effectiveness, so it may not shrink tumors or help patients live longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
FSBI National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation
Moscow, 117630, Russia